CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.

CalciMedica, Inc.

CalciMedica is developing therapeutics that inhibit CRAC channels to address life-threatening inflammatory diseases affecting the pancreas, kidney, and lung.

CalciMedica

CalciMedica | 1,134 followers on LinkedIn. Leader in the development of CRAC channel inhibitor drugs for inflammatory diseases | CalciMedica is a privately held, clinical stage biotechnology company with a platform focused on CRAC channel drug discovery and development for the treatment of acute and severe inflammatory diseases. The Company was founded in 2007 by Ken Stauderman, CalciMedica’s Chief Scientific Officer, and colleagues at Torrey Pines Therapeutics in San Diego and Harvard’s Center for Blood Research in Cambridge, MA. Dr.

Frederic Guerard

Founder and Managing Director at Danforth Advisors

Daniel Geffken

Chief Regulatory Officer CalciMedica

Raven Jaeger

SVP, Clinical Development at CalciMedica

Andrew Cunningham

We are delighted to welcome Stephen Bardin to the CalciMedica team as Chief Financial Officer, and look forward to working together as we continue to advance our clinical-stage pipeline. Read the press release: https://lnkd.in/excRjSrX

We are excited to be presenting the full data set from our Phase 2b CARPO trial of Auxora in #acutepancreatitis on a conference call and webcast, during which Prof. Robert Sutton will deliver his plenary presentation from the American College of Gastroenterology (ACG) Annual Scientific Meeting. See our press release for a description of the late-breaking, positive data, including a win ratio analysis, and for instructions to join the webcast: https://lnkd.in/eqDePnKK

We are pleased to announce a late-breaking abstract for a plenary presentation by Prof. Robert Sutton from the University of Liverpool at American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. Details in the press release: https://lnkd.in/egniHv87 #ACG2024

Earlier this week we shared the news that the first patient has been dosed in #KOURAGE , our Phase 2 trial evaluating Auxora for the treatment of severe acute kidney injury with associated acute hypoxemic respiratory failure (AHRF). There are currently no approved therapies for AKI and we look forward to continuing to evaluate Auxora as a potential treatment for this severe and underserved disease. See our press release: https://lnkd.in/e8HzWKjJ

Today we announced that the first patient has been dosed in #KOURAGE , our Phase 2 trial evaluating Auxora for the treatment of severe #acutekidneyinjury with associated acute hypoxemic respiratory failure (AHRF). We expect to share topline data from this trial in 2025. Read the press release: https://lnkd.in/eRmNxsik

We are excited to share that today we announced positive topline data from our Phase 2b CARPO trial of #Auxora in #acutepancreatitis (AP). The trial established a dose response for Auxora across multiple endpoints, identified both the target patient population and the likely drug dose for a pivotal trial, and re-affirmed Auxora’s safety profile and tolerability as seen in prior clinical trials. Read the press release: https://lnkd.in/gAgBCaAW

We recently completed enrollment in our ongoing Phase 2b clinical trial, CARPO, which is evaluating Auxora™ in patients with #acutepancreatitis with accompanying SIRS. For details on the clinical trial, visit https://lnkd.in/eTwrEFCa , or hear some of our study investigators discuss the potential for #Auxora to improve outcomes for patients with AP.

Today we announced that the last patient has been enrolled in our Phase 2b CARPO trial of Auxora™ in #acutepancreatitis (AP). Details here: https://lnkd.in/eqjarCww

Today CalciMedica reported financial results for the year ended December 31, 2023. Read the press release here: https://lnkd.in/eEFNhNSK

Yesteday we presented data from preclinical studies of Auxora in acute kidney injury at the 29th International AKI & CRRT Conference. The data show that Auxora hastens recovery of kidney function and improves survival in a rat model of #AKI . https://lnkd.in/g5h4vxbY

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
average inventory					-19.50K -	-19.50K 0%
average payables		3.58M -	3.57M 0.14%	1.52M 57.48%	1.12M 26.22%	1.57M 39.77%
average receivables					19.50K -	19.50K 0%
book value per share	14.02 -	27.50 96.14%	200.50 629.12%	42.94 78.58%	23.43 45.43%
capex per share	-1.70 -	-0.59 65.64%	-2.16 269.52%	-0.32 85.11%	-1.47 355.25%
capex to depreciation	-8.35 -	-2.00 76.08%	-2.59 29.71%	-0.94 63.69%	-6.66 608.60%	-1.34 79.82%
capex to operating cash flow	0.05 -	0.02 62.57%	0.03 64.61%	0.02 51.44%	0.10 535.36%	0.00 96.92%
capex to revenue
cash per share	14.97 -	34.80 132.48%	201.02 477.58%	42.05 79.08%	25.49 39.37%
days of inventory on hand
days payables outstanding
days sales outstanding
debt to assets					0.01 -
debt to equity					0.01 -
dividend yield
earnings yield	-5.67 -	-6.14 8.30%	-9.97 62.44%	-4.05 59.38%	-3.97 1.94%
enterprise value	-7.83M -	-9.84M 25.67%	-30.66M 211.66%	-4.52M 85.25%	-8.14M 79.99%	-5.53M 32.04%
enterprise value over ebitda	0.28 -	0.26 4.07%	1.03 288.62%	0.13 87.76%	0.27 116.27%
ev to operating cash flow	0.28 -	0.32 13.60%	0.96 203.41%	0.14 84.99%	0.36 147.81%	0.21 39.57%
ev to sales
free cash flow per share	-34.62 -	-30.80 11.03%	-69.99 127.23%	-21.12 69.82%	-16.37 22.50%
free cash flow yield	-5.93 -	-5.27 11.03%	-11.98 127.23%	-3.62 69.82%	-2.80 22.50%
graham net net	8.21 -	22.95 179.42%	186.20 711.48%	39.36 78.86%	23.09 41.35%
graham number	102.19 -	148.94 45.75%	512.56 244.15%	151.18 70.50%	110.59 26.85%
income quality	0.99 -	0.84 15.24%	1.16 38.19%	0.88 24.49%	0.64 26.93%	0.75 16.55%
intangibles to total assets	0 -	0	0	0	0	0
interest coverage			-208.62 -	-285.29 36.76%
interest debt per share			0.30 -	0.08 72.49%	0.13 58.94%
inventory turnover
invested capital					0.01 -
market cap	5.01M -	6.03M 20.51%	2.76M 54.24%	8.84M 220.31%	8.96M 1.37%
net current asset value	7.65M -	24.02M 213.95%	92.23M 283.98%	63.01M 31.68%	35.97M 42.91%	7.58M 78.94%
net debt to ebitda	0.45 -	0.43 5.61%	1.12 162.57%	0.37 66.81%	0.57 53.76%
net income per share	-33.10 -	-35.85 8.30%	-58.24 62.44%	-23.66 59.38%	-23.20 1.94%
operating cash flow per share	-32.91 -	-30.22 8.20%	-67.83 124.47%	-20.80 69.33%	-14.91 28.35%
payables turnover
receivables turnover
research and ddevelopement to revenue
return on tangible assets	-1.59 -	-0.91 42.82%	-0.27 70.31%	-0.52 91.71%	-0.90 73.11%
revenue per share
roe	-2.36 -	-1.30 44.78%	-0.29 77.72%	-0.55 89.67%	-0.99 79.68%
roic	-2.38 -	-1.31 45.06%	-0.31 76.37%	-0.52 69.17%	-1.06 103.31%
sales general and administrative to revenue
shareholders equity per share	14.02 -	27.50 96.14%	200.50 629.12%	42.94 78.58%	23.43 45.43%
stock based compensation to revenue
tangible asset value	12.02M -	28.41M 136.37%	94.79M 233.65%	65.02M 31.40%	35.97M 44.68%	8.16M 77.32%
tangible book value per share	14.02 -	27.50 96.14%	200.50 629.12%	42.94 78.58%	23.43 45.43%
working capital	7.65M -	24.02M 213.95%	92.24M 284.03%	63.02M 31.68%	35.97M 42.92%	7.58M 78.94%

COM:CALCIMEDICA

CalciMedica

Last Close

3.45

22/11 21:00

Market Cap

49.23M

Beta: -

Volume Today

27.23K

Avg: -

Preview